Regencell Bioscience
4 hedge funds and large institutions have $18.9K invested in Regencell Bioscience in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
42% less capital invested
Capital invested by funds: $32.3K → $18.9K (-$13.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.6K |
| 2 |
Morgan Stanley
New York
|
+$448 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$18.7K |
RGC Hedge Fund Activity: Q1 2023 in Review
4 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q1 2023, worth a combined $18.9K — down 42% from $32.3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new RGC positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $5.6K. The largest seller was UBS Group, cutting an estimated $18.7K.
- 4 institutional investors held Regencell Bioscience (RGC) as of Q1 2023, up from 3 in Q4 2022.
- Funds reported $18.9K of Regencell Bioscience stock for Q1 2023, down 42% quarter-over-quarter.
- 1 fund opened new Regencell Bioscience positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest Regencell Bioscience buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $5.6K added.
- The largest Regencell Bioscience seller in Q1 2023 was UBS Group, an estimated $18.7K sold.
Based on aggregated 13F filings for Q1 2023.